Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVID-670
- Development stage
- Preclinical
- Lead developer
- AdCure Bio
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
AVID-670 is an engineered oncolytic adenovirus being developed by AdCure Bio for the treatment of solid tumors, including non-small cell lung cancer (NSCLC). Designed as a sequential systemic therapeutic, AVID-670 is administered intravenously to selectively infect and lyse tumor cells. The platform aims to overcome the limitations of traditional oncolytic viruses by enabling systemic delivery, which allows the virus to reach metastatic sites and primary tumors throughout the body. By inducing tumor cell lysis, the therapy may also stimulate a systemic anti-tumor immune response. It is currently in the preclinical discovery and refinement stage.
Beyond the preview
Go deeper on AVID-670.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVID-670.